We have developed a new simple solid-phase luminescence immunoassay (L
IA) for the determination of faecal lysozyme. The assay utilises a pol
yclonal capture antibody coated to polystyrene beads and acridinium es
ter-labelled human lysozyme as tracer. Samples are incubated with poly
styrene beads and tracer overnight at 4 degrees C, After a thorough wa
shing step, emitted light is measured by an automated luminometer for
2 seconds. The standard curve uses five standards ranging from 0.025 t
o 6.4 mg/l. The method has a sensitivity of 0.02 mg/l. Dilution recove
ries for three samples were 88, 104 and 108%. Intraassay coefficients
of variation (CV, n = 24) were 10.1% and 11.7% for a healthy control a
nd a patient sample; interassay CV (n = 16) were 6.7% and 13.1% for th
e same healthy control but another patient sample. The normal range of
faecal lysozyme in 80 healthy controls was found to be 0.02-1 mg/l (9
7.5 percentile) with a median of 0.28 mg/l, Fifty-three patients with
Crohn's disease had faecal lysozyme values ranging from 0.16 to 100.7
mg/l with a median of 1.75 mg/l, and 30 patients with ulcerative colit
is showed levels between 0.09 and 118 mg/l with a median of 1.11 mg/l.
The assay has proved useful for differentiating healthy individuals f
rom those with inflammatory bowel disease and might be a valuable tool
for diagnosing or evaluating inflammatory bowel disease.